GG
SPRO icon

Gofen & Glossberg’s Spero Therapeutics SPRO Stock Holding History

Gofen & Glossberg’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$30K Hold
17,500
– – ﹤0.01% 561
2022
Q3 		$35K Hold
17,500
– – ﹤0.01% 541
2022
Q2 		$13K Hold
17,500
– – ﹤0.01% 560
2022
Q1 		$152K Hold
17,500
– – ﹤0.01% 561
2021
Q4 		$280K Hold
17,500
– – 0.01% 474
2021
Q3 		$322K Hold
17,500
– – 0.01% 423
2021
Q2 		$244K Hold
17,500
– – 0.01% 490
2021
Q1 		$258K Hold
17,500
– – 0.01% 443
2020
Q4 		$339K Buy
17,500
+7,500
+75% +$117K 0.01% 373
2020
Q3 		$112K Buy
+10,000
New +$118K ﹤0.01% 457

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Gofen & Glossberg's SPRO Position: Q4 2022 in Review

Gofen & Glossberg held its Spero Therapeutics (SPRO) position steady in Q4 2022 at 17,500 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #561.

Gofen & Glossberg first reported a position in SPRO in Q3 2020 and has held it in 10 quarters since. The position peaked at $339K in Q4 2020. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

  • Gofen & Glossberg held 17,500 shares of Spero Therapeutics worth $30K as of Q4 2022.
  • Gofen & Glossberg left its Spero Therapeutics share count unchanged in Q4 2022.
  • Spero Therapeutics made up ﹤0.01% of Gofen & Glossberg's portfolio in Q4 2022, its #561 holding.
  • Gofen & Glossberg first reported a position in Spero Therapeutics in Q3 2020 and has held it in 10 quarters since.
  • Gofen & Glossberg's Spero Therapeutics position peaked at $339K in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on Gofen & Glossberg's 13F filing for Q4 2022, filed 13 Jan 2023.